Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Biliary Tract Neoplasms
- Breast Neoplasms
- Carcinoma Non-small-cell Lung
- Urologic Neoplasms
- Uterine Cervical Neoplasms
- Uterine Neoplasms
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
There are multiple cohorts in this trial: 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer [NSCLC]) 2 tumor specific cohorts with HER2 mutations (non-squamous NSCLC a...
There are multiple cohorts in this trial: 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer [NSCLC]) 2 tumor specific cohorts with HER2 mutations (non-squamous NSCLC and breast cancer) 2 cohorts which will enroll all other HER2 amplified/overexpressed solid tumor types (except breast cancer, GEC, and CRC) or HER2-mutated solid tumor types.
Tracking Information
- NCT #
- NCT04579380
- Collaborators
- Not Provided
- Investigators
- Study Director: Vicky Kang, MD Seagen Inc.
Get Well Soon